• Q1 new TCV sales of $8.2M
• Q1 FY26 operating cash outflow of $0.6M, a material improvement vs. $3.9M outflow in Q1 FY25
• FY26 contracted (sold and renewal) revenue of $36.3M as of 30 September 2025

Alcidion Group Limited (ASX: ALC) has released its Appendix 4C and Quarterly Activities Report for the quarter ended 30 September 2025 (Q1 FY26). Key highlights include Q1 new TCV sales of $8.2M, with 92% recurring product revenue and 8% non-recurring services revenue. The company also reported a material improvement in Q1 FY26 operating cash outflow of $0.6M, compared to $3.9M outflow in Q1 FY25. As of 30 September 2025, Alcidion has FY26 contracted (sold and renewal) revenue of $36.3M, with new sales expected to increase this figure over the remaining 9 months of the year. The company reconfirmed FY26 guidance to deliver positive EBITDA and operating cashflow. Alcidion CEO Kate Quirke noted the pleasing first quarter performance, which sets the company up with strong foundations for the remainder of the year. The company continues to expand its relationships with existing customers, such as the $6.8M expansion to the North Cumbria contract, and has successfully deployed its Miya solutions at new sites, including University Hospitals Southampton NHS Foundation Trust and North Adelaide Local Health Network.

Alcidion reconfirms FY26 guidance to deliver positive EBITDA and operating cashflow, with the quantum dependent on the timing of contracts progressing through the procurement stages.

As of 30 September 2025, Alcidion has FY26 contracted (sold and renewal) revenue of $36.3M, with new sales expected to increase this figure over the remaining 9 months of the year.